Prostate Cancer Prevention

1. Front Matter

   Pages i-viii

   PDF

2. The Biology and Natural History of Prostate Cancer: A Short Introduction

   • Lars Holmberg, Mieke Van Hemelrijck

   Pages 1-7

3. Germline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice

   • Chee Leng Goh, Rosalind Anne Eeles

   Pages 9-26

4. Lifestyle and Dietary Factors in Prostate Cancer Prevention

   • Andrea Discacciati, Alicja Wolk

   Pages 27-37

5. Nutrition, Hormones and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition

   • Timothy J. Key

   Pages 39-46

6. Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues

   • Fritz H. Schröder

   Pages 47-51

7. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

   • Gerald L. Andriole

   Pages 53-57

8. ERSPC, PLCO Studies and Critique of Cochrane Review 2013

   • Fritz H. Schröder

   Pages 59-63

9. Screening for Prostate Cancer: Reflecting on the Quality of Evidence from the ERSPC and PLCO Studies

   • Dragan Ilic

   Pages 65-71

10. Phase III Prostate Cancer Chemoprevention Trials

    • Howard L. Parnes, Otis W. Brawley, Lori M. Minasian, Leslie G. Ford

    Pages 73-77

11. Risk Adapted Chemoprevention for Prostate Cancer: An Option?

    • Bernd J. Schmitz-Dräger, Oliver Schöffski, Michael Marberger, Sevim Sahin, Hans-Peter Schmid

    Pages 79-91

12. Aspirin and Prostate Cancer Prevention

    • Cristina Bosetti, Valentina Rosato, Silvano Gallus, Carlo La Vecchia

    Pages 93-100

13. Chemoprevention of Prostate Cancer by Isoflavonoids

    • Stefan Aufderklamm, Florian Miller, Anastasia Galasso, Arnulf Stenzl, Georgios Gakis

    Pages 101-108

14. Lycopene for the Prevention and Treatment of Prostate Disease

    • Dragan Ilic

    Pages 109-114

15. Chemoprevention of Prostate Cancer with the Polyamine Synthesis Inhibitor Difluoromethylornithine

    • Frank L. Meyskens Jr., Anne R. Simoneau, Eugene W. Gerner

    Pages 115-120

16. Prostate Cancer Prevention: Agent Development Strategies

    • Howard L. Parnes, Margaret G. House, Joseph A. Tangrea

    Pages 121-131

17. Prognostic Value of a Cell Cycle Progression Score for Men with Prostate Cancer

    • Jack Cuzick

    Pages 133-140

18. Distinguishing Indolent from Aggressive Prostate Cancer

    • Zoran Culig

    Pages 141-147

19. Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial

    • Timothy J. Wilt

    Pages 149-169

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

• Biomarkers
• Chemoprevention
• Early Detection
• Prostate Cancer
• Risk-prevention

From the reviews:

“Part of the Recent Advances in Cancer Research series, this book’s title suggests that it tackles prevention of prostate cancer. … scientists and clinicians who deal with prostate cancer are the main audience. … The discussion of agent development and strategies is very useful to anyone looking to tackle the challenging area of prostate cancer chemoprevention.” (Leonard G. Gomella, Doody’s Book Reviews, May, 2014)

• Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

  Jack Cuzick, Mangesh A. Thorat

Policies and ethics